Another anti-TIM-3 mAb under investigation is MGB453, for which the safety and efficacy have already been evaluated, both alone and in combination with PDR001 (an anti-PD-1 mAb) in patients with advanced cancers [153]. This evidence concerns the gene HAVCR2 and cancer.